Long-Term Assessment of the Safety and Performance of the NuVasive Simplify Disc at Two Levels

• Conditions: Degenerative Disc Disease; Cervical Disc Disease
• Interventions: Device: NuVasive Simplify Cervical Artificial Disc

• Registration Number: NCT05691231
• Lead Sponsor: NuVasive

Brief Summary

A prospective, multicenter post-market clinical follow-up study to evaluate the 10-year long-term safety and effectiveness of the Simplify Disc at two levels in subjects who were enrolled in the IDE study (NCT03123549) and/or post approval study (NCT04980378).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-01-11
• Study First Submitted QC: 2023-01-11
• Study Start: 2023-01-18
• Study First Posted: 2023-01-19
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-19
• Last Update Posted: 2025-05-22
• Primary Completion: 2029-02-10
• Study Completion: 2029-05-10

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 158

Inclusion Criteria

1. Subject was enrolled in the Simplify Disc IDE (NCT03123549) and/or PAS (NCT04980378) at a participating study site
2. Patient understands the conditions of enrollment and is willing sign an informed consent form to participate in the study

Exclusion Criteria

1. Subject had an SSI at the index level during the IDE study (NCT03123549) or the PAS (NCT04980378)
2. Subject was withdrawn or withdrew consent to participate in the IDE study (NCT03123549) or PAS (NCT04980378)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Simplify Disc	NuVasive Simplify Cervical Artificial Disc	Extended follow-up of subjects treated with the Simplify Disc during IDE study NCT03123549 and followed in the post-approval study NCT04980378.

Primary Outcome Measures

Name	Time	Method
Clinical Composite Success Rate	10 years	Individual success is defined as at least a 15 point improvement in Neck Disability Index (NDI) Score at 120 months compared with baseline, maintenance or improvement in neurologic status at 120 months compared with baseline, no additional surgical procedure at the index level within 120 months, and the absence of a serious adverse event classified as implant-associated or implant/surgical procedure-associated within 120 months. A subject must meet each criterion to be considered an overall study success.; NDI scale is reported in a range from 0 - 100, with 0 consistent with best ability to function and 100 with worst ability to function.

Secondary Outcome Measures

Name	Time	Method
Disc height at each annual timepoint will be compared to baseline	10 years	Average disc height is calculated as the simple average of the anterior and posterior disc heights
Range of motion (ROM) at each annual timepoint compared to baseline	10 years	Changes in Global Range of Motion will be calculated by subtracting the range of motion measured at one time point from the baseline range of motion. Change in Global Range of Motion will be reported in units of degrees.
Dysphagia Handicap Index1 (DHI) at each annual timepoint compared to baseline	10 years	DHI is scored from 0-100, with a higher score indicative of a less desirable outcome.
Adjacent level disc degeneration (ALDD) at each annual timepoint will be compared to baseline	10 years	ALDD is graded in accordance with definitions adapted from Kellgren and Lawrence: None; Doutbtful;Minimal;Moderate;Severe
Displacement or migration of the Simplify Disc at each annual timepoint will be compared to the post-op timepoint in the IDE study (NCT03123549)	10 years	Device migration assesses significant movement of the implant postoperatively. Changes of \>3 mm will be considered significant due to the margin of error in radiographic determination of displacement distances.
Rate of adverse events attributable to Simplify Disc, or use of additional NuVasive instruments, implants, or technologies at each annual timepoint	10 years	Number of adverse events related to Simplify Disc or additional NuVasive products
Patient satisfaction and perceived effect at each annual timepoint	10 years	Patient questionnaire assessing satisfaction with treatment and perceived effect of treatment. Success for each satisfaction question will be defined as either a "Definitely True" or "Mostly True" response. Success for the perceived effect question will be defined as either a "Completely Recovered," "Much Improved," or "Slightly Improved" response.
Motor status at each annual timepoint compared to baseline	10 years	A change of one or more grade levels in muscle strength will be regarded as clinically significant.
SF-36® Health Survey at each annual timepoint compared to baseline	10 years	The SF-36 is a multipurpose survey with 36 questions. The questions were combined, scored and weighted to create mental and physical functioning and overall health-related quality of life. Higher scores indicate better outcomes. Scores range from 0-100.
Percentage of subjects meeting the minimal clinically important difference (MCID) for NDI at each annual timepoint	10 years	Neck Disability Index; scale is reported in a range from 0-100, with 0 consistent with best ability to function and 100 worst ability to function.
Percentage of subjects meeting MCID for neck and arm pain questionnaire for each of the following pain locations: neck pain, arm pain, left arm pain, right arm pain.	10 years	Neck and arm pain questionnaire, scale is reported in a range from 0 to 10, with 0 consistent with no pain and 10 with most pain
Sensory status at each annual timepoint compared to baseline	10 years	Sensation will be graded as normal or abnormal (diminished or absent). Any changes from abnormal to normal or absent to diminished will be regarded as clinically significant improvement.

Trial Locations

Locations (2)

Texas Back Institute; 🇺🇸 Plano, Texas, United States

Carolina Neurosurgery and Spine Associates; 🇺🇸 Charlotte, North Carolina, United States